leadf
logo-loader
viewMagicMed Industries Inc

MagicMed Industries files provisional patent covering psychedelic derivatives

The company expects the filing to be the first in a series of applications that together are designed to protect its portfolio of novel derivatives known as the Psybrary

Magic mushrooms
MagicMed’s approach is to partner with pharmaceutical and other companies who can use its Psybrary as a building block to develop new patented products

MagicMed Industries Inc announced Thursday that it has filed a provisional patent application with the US Patent and Trademark Office (USPTO) related to the composition of matter, drug formation and the process of preparation for novel psilocybin derivatives. 

The Calgary-based company expects the filing to be the first in a series of applications that together are designed to protect its portfolio of novel derivatives known as the Psybrary.

MagicMed partners will be able to search, select and test from the derivatives that are part of the Psybrary and use them as building blocks for their own products, such as treatments for anxiety, addiction, PTSD and other conditions, the company said. 

“We are excited by the new opportunities to partner with pharmaceutical manufacturers afforded by the library of derivatives that this patent application claims,” MagicMed CEO Joseph Tucker said in a statement.

“Our business model is to work hand in hand with pharma partners to assist them in taking excellent medicinal product candidates forward. In fact, we have already initiated talks with potential partners to assist them in the development of new therapies for diverse psychological indications,” he added.

Psilocybin is a naturally occurring molecule with therapeutic potential for multiple psychological indications that are currently inadequately treated, the company said. The medical applications are encouraging, and the primary goal is to maximize its positive attributes while limiting its potential negative side effects, such as hallucinations and panic attacks. 

MagicMed’s approach is to partner with pharmaceutical and other companies who can use the Psybrary as a building block to develop new patented products.

Contact Andrew Kessel at [email protected]nvestors.com

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MagicMed Industries Inc named herein, including the promotion by the Company of MagicMed Industries Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

MagicMed CEO talks the past, present, and most importantly the future of...

MagicMed Industries CEO Dr Joseph Tucker joined Steve Darling from Proactive Vancouver to have a look at where his industry had been in the past, where things are at right now and where he sees the future of Pshycadelics going into the future.           

on 09/24/2020

2 min read